TRIM-edicine brings together management, scientific advisors, intellectual property expertise and scientific leadership supporting its therapeutic programs.
Dr. Qiu has more than two decades of investment experience in venture capital and private equity, including biotechnology, medical devices and CRO companies. His experience spans due diligence, deal structuring, financing, mergers and acquisitions, IPO preparation, corporate strategy, business development and investor communications. He earned an M.B.A. from Columbia Business School and a doctorate from Colorado School of Mines.
Dr. Tan is a physician-scientist with doctoral training in physiology and integrative biology. She joined TRIM-edicine in 2009, has co-authored more than 30 publications in molecular medicine, and leads research and development while contributing to company management.
Dr. Abraham is a cardiologist and heart-failure specialist with extensive clinical and translational research experience. His work includes heart-failure mechanisms and clinical drug and device trials, and he has served as a scientific advisor for the translational development of MG53.
Dr. John has more than twenty years of experience in pharmaceutical development, project management and regulatory affairs. Her work has included IND applications for drugs and biologics and interactions with regulatory authorities in the United States, Canada, New Zealand and Australia. She held development and regulatory roles at Neorx, NewBiotics/Celmed Biosciences, Proacta, Centegen and EnzymeRx. She received her Ph.D. in Chemistry from Rutgers University and completed postdoctoral research at Purdue University.
Dr. Matos is the founder of Innovar, L.L.C. and has more than thirty years of pharmaceutical experience as a researcher, patent practitioner and consultant. His work integrates intellectual property, business and R&D strategy, including development and management of pharmaceutical patent portfolios. He earned his doctorate in Bioorganic Chemistry from Texas A&M University and previously worked at DuPont Merck Pharmaceutical Company before founding Innovar in 2000.
Dr. Ma is the founder of TRIM-edicine. He earned his bachelor's degree in Physics from Wuhan University and his Ph.D. in Physiology and Biophysics from Baylor College of Medicine. His research in gene discovery, tissue repair, muscular dystrophy, cardiovascular disease, aging biology and cancer underpins major elements of the company's MG53, MG29 and membrane-repair technology portfolio.